OpenNeedle Ask your own

Question explored with the scientific record

What are symptoms of low testosterone

Sep 6, 2026 · 7 sources used · OpenNeedle synthesis
The short version: low testosterone shows up in sexual function, body composition, mood, energy, and bone density, but the evidence is mostly from observational studies and manufacturer-funded trials, not long-term population data.

The symptoms of low testosterone cluster into several domains. Sexual symptoms are the most consistently linked: low libido, erectile dysfunction, and reduced ejaculatory function show statistically significant correlations with low testosterone levels in studies of hypogonadal men [9, 10]. One study of 22 men found that testosterone therapy improved sexual desire in all 22 and erectile function in 12 of them [11]. But the same review notes that testosterone replacement improves erectile function in only 40-60% of patients, meaning a substantial fraction do not respond [10]. The evidence is clearer for libido than for erections.

Beyond sex, the symptom list from a narrative review of Central Asian populations includes fatigue, decreased muscle mass and strength, increased body fat, decreased bone density, and mood changes [3]. A 2022 Italian guideline confirms that testosterone therapy can improve body composition (decrease fat mass, increase lean mass) and vertebral bone density, though fracture data is thin [14]. The same guideline notes that mood and cognitive effects are mixed and not proven. Anemia is also linked: a 2023 JAMA trial found that testosterone therapy corrected anemia in 41-45% of hypogonadal men versus 28-33% on placebo [16], and a 2011 CKD study found low testosterone increased anemia risk and reduced response to erythropoiesis-stimulating agents [19].

Symptom domainEvidence strengthNotes
Low libidoModerateMost consistent sexual symptom [9, 10]
Erectile dysfunctionModerateImproves in 40-60% with TRT [10]
Decreased muscle mass / increased fatModerateTRT improves body composition [14]
Bone density lossModerateTRT improves vertebral BMD [14]
Fatigue / low energyWeakListed but not well-quantified [3]
AnemiaModerateTRT corrects anemia in ~40% [16]
Mood changesWeakMixed evidence per guidelines [14]

The evidence base has real limits. Most of it comes from small studies, narrative reviews, and manufacturer-funded trials. The 2023 JAMA trial was funded by the manufacturer [16]. The Italian guideline is a consensus document, not a fresh trial [14]. No large long-term study compares treated to untreated men on all-cause mortality or fracture rates. The burden of proof for testosterone therapy itself is on the intervention, and the evidence for symptom relief is moderate at best, not strong.

My call: low testosterone causes real symptoms in sexual function, body composition, and bone density, but the evidence is moderate and the treatment effect is partial. Confidence: moderate.

Keep digging

Sources used 7

  1. LOW TESTOSTERONE LEVELS IN ADULTS IN CENTRAL ASIA REGIONS Grail of Science (2023) Thin

    This article provides a narrative overview of low testosterone levels among adults in Central Asia, discussing prevalence drivers (e.g., obesity, vitamin D deficiency), health consequences, and treatment/prevention options.

    DOI: 10.36074/grail-of-science.17.03.2023.084
  2. Changes in body composition, lipid profile, serum fibrinogen, serum fasting glucose and red blood cell count in men on log-term androgen deprivation therapy Journal of Men's Health (2009) Thin

    This study investigates the correlation between baseline serum testosterone levels and sexual function in hypogonadal men with erectile dysfunction, revealing significant associations between testosterone levels and various domains of the Brief Male Sexual Function Inventory (BM…

    DOI: 10.1016/j.jomh.2009.08.084
  3. Hypogonadism and erectile dysfunction: the role for testosterone therapy International Journal of Impotence Research (2003) narrative review Strong

    In hypogonadal men with erectile dysfunction, testosterone therapy may augment ED treatment, particularly when combined with PDE5 inhibitors; testosterone alone often does not reliably restore erectile function.

    DOI: 10.1038/sj.ijir.3901030
  4. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®) World Journal of Urology (2006) Thin

    This study investigates the effects of long-acting testosterone undecanoate (Nebido) on sexual dysfunction in hypogonadal men, demonstrating significant improvements in sexual desire and erectile function in a majority of patients after treatment.

    DOI: 10.1007/s00345-006-0120-0
  5. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE) Journal of Endocrinological Investigation (2022) Thin

    This article provides updated, evidence-based clinical practice guidelines from the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE) on the diagnosis, treatment, monitoring, and safety of testosterone therapy for adult-onset…

    DOI: 10.1007/s40618-022-01859-7
  6. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism JAMA Network Open (2023) Thin

    In a multicenter, randomized, placebo-controlled trial nested within the TRAVERSE study, testosterone replacement therapy significantly increased correction of anemia in men with hypogonadism and reduced the incidence of anemia in those without baseline anemia, with associated i…

    DOI: 10.1001/jamanetworkopen.2023.40030
  7. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease Nephrology Dialysis Transplantation (2011) Thin

    This study investigates the association between testosterone deficiency and anemia in men with chronic kidney disease, revealing that low testosterone levels significantly increase the likelihood of anemia and reduce responsiveness to erythropoiesis-stimulating agents.

    DOI: 10.1093/ndt/gfr288

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question